References
- National Multiple Sclerosis Society. “About MS: bladder dysfunction”. Available from http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/symptoms/bladder-dysfunction/index.aspx.
- Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113:5S–13S.
- Edlich RF, Westwater JJ, Lombardi SA, Watson LR, Howards SS. Multiple sclerosis and asymptomatic urinary tract infection. J Emerg Med 1990;8:25–8.
- Sand PK, Sand RI. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. Dis Mon 2013;59:261–8.
- Metz LM, McGuinness SD, Harris C. Urinary tract infections may trigger relapse in multiple sclerosis. Axone 1998;19:67–70.
- Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952–60.
- Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652–9.
- Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553–62.
- Ampyra [dalfampridine] extended release (ER) tablets highlights of prescribing information. Acorda Therapeutics, Inc; Ardsley, NY: January 2014.
- Goodman AD, Brown TR, Krupp LB, et al. Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732–8.
- Goodman AD, Brown TR, Edwards KR, et al. MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494–502.
- Jara M, Barker G, Henney HR3rd. Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Neuropsychiatr Dis Treat 2013;9:365–70.
- Jara M, Adera M, Adedeji A, Henney H, Carrazana E. Dalfampridine extended release tablets: safety profile after 2 years of post-marketing experience in the United States [ECTRIMS abstract P1026]. Mult Scler 2012;18:476–7.
- Goodman AD, Brown TR, Cohen JA, et al. Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134–41.
- Yapundich R, Applebee A, Bethoux F, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: a randomized, controlled trial. Int J MS Care 2014; In press.
- Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–6.
- Kunin CM, White LV, Hua TH. A reassessment of the importance of “low-count” bacteriuria in young women with acute urinary symptoms. Ann Intern Med 1993;119:454–60.
- Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004;38:1150–8.
- Mehnert-Kay SA. Diagnosis and management of uncomplicated urinary tract infections. Am Fam Physician 2005;72:451–6.
- Blight AR, Henney HR3rd. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328–35.